An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma
The study is closed and all subjects have completed treatment.
The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in
subjects with non-cutaneous T cell lymphoma. The primary efficacy will be evaluated by time
to relapse.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy as measured by survival and time to disease progression
12 months
No
Abhay Patki, PhD
Study Chair
Genmab
Denmark: Danish Medicines Agency
Hx-CD4-109
NCT00877656
August 2005
December 2008
Name | Location |
---|